
Foundayo Heart Safety: What the ACHIEVE-4 Trial Found in Type 2 Diabetes
Updated: Oct 28
Written and medically reviewed by Dr. Baraa Alnahhal, MD · Last reviewed: October 2026
Foundayo heart safety now has its first large answer. In a two-year trial of 2,749 adults with type 2 diabetes and a high risk of heart disease, the once-daily GLP-1 pill Foundayo (orforglipron) was no worse than insulin glargine at preventing heart attacks, strokes, heart-related deaths and hospital stays for unstable chest pain. The results were published in The Lancet on September 30, 2026, and presented at the European Association for the Study of Diabetes (EASD) meeting in Milan (The Lancet; Eli Lilly) [1] [2].

The short version: the pill passed its safety test for the heart. Fewer people died in the pill group, but that finding needs caution, as explained below.
Quick Answer: Is Foundayo safe for the heart?
Foundayo (orforglipron) is a once-daily GLP-1 pill that, in the two-year ACHIEVE-4 trial of 2,749 adults with type 2 diabetes and high heart risk, was no worse than insulin glargine at preventing major heart events. These occurred in 4.2% on the pill and 5.0% on insulin. [1] Stomach side effects were common [1], and US approval covers weight management only. [3]
What the research says
Better blood sugar than oral semaglutide. In a 52-week trial of 1,698 adults with type 2 diabetes, orforglipron lowered HbA1c by 1.71–1.91%, compared with 1.23–1.47% for oral semaglutide (Rybelsus). The trade-off: more stomach side effects (58–59% vs 37–45%), and about twice as many people stopped the drug because of side effects (9–10% vs 4–5%) (Rosenstock et al., The Lancet, 2026) [5].
Works when added to insulin. In 546 adults already on insulin glargine, adding orforglipron lowered HbA1c by 1.58–1.88% over 40 weeks, vs 0.79% with placebo. Weight fell by 2.6–5.4%, with no rise in serious low blood sugar (Giorgino et al., JAMA, 2026) [6].
Helps keep weight off after injections. People who had lost weight on tirzepatide or semaglutide injections, then switched to the pill, kept about 75–79% of their weight loss after one year. People switched to placebo kept 38–49% (Aronne et al., Nature Medicine, 2026) [7].
Key takeaways
The ACHIEVE-4 trial compared Foundayo with insulin glargine in 2,749 adults with type 2 diabetes, overweight or obesity, and existing heart or kidney disease (The Lancet) [1].
Major heart events happened in 4.2% of people on the pill and 5.0% on insulin. This met the trial's goal of showing the pill is "not worse" for the heart (The Lancet) [1].
Deaths were lower with the pill (1.4% vs 3.2%), but this was not the trial's main question and should not be read as proof that the pill saves lives (The Lancet; Eli Lilly) [1] [2].
At one year, people on the pill lost about 8.8% of their body weight; people on insulin gained about 1.7% (Eli Lilly) [2].
Stomach side effects were common: 62.1% on the pill vs 14.2% on insulin. Dangerous low blood sugar was less common on the pill (The Lancet) [1].
In the US, Foundayo is approved for weight management, not yet for type 2 diabetes (Lilly Medical) [3].
What is Foundayo (orforglipron)?
Foundayo is the brand name of orforglipron, a once-daily pill in the GLP-1 receptor agonist family. GLP-1 medicines copy a natural gut hormone that helps control blood sugar and appetite. Most older GLP-1 medicines are injections and are built from proteins (peptides). Orforglipron is different: it is a small, non-peptide molecule taken by mouth (The Lancet) [1].
The US Food and Drug Administration (FDA) approved Foundayo on April 1, 2026, for long-term weight management in adults with obesity, or with overweight plus at least one weight-related health condition, together with diet and exercise (Lilly Medical) [3]. Its use for type 2 diabetes is still under study.
Why does Foundayo heart safety matter for people with diabetes?
Heart disease is the main worry for many people with type 2 diabetes. People with diabetes have about twice the risk of heart disease, and high blood sugar can damage blood vessels and the nerves that control the heart over time (CDC) [4].
Some injectable GLP-1 medicines have already shown heart benefits in large trials. But no non-peptide GLP-1 pill had been tested this way before ACHIEVE-4 (The Lancet) [1]. Any new diabetes medicine must show that it does not raise heart risk, so this trial was an important checkpoint.
How was the ACHIEVE-4 trial designed?
The ACHIEVE-4 trial randomly assigned adults with type 2 diabetes and heart or kidney disease to daily Foundayo pills or insulin glargine and compared heart events.
Who took part: 2,749 adults at 317 sites in 16 countries. All had type 2 diabetes, a body mass index (BMI) of 25 or more, and established heart disease or chronic kidney disease. Their average age was 63, and their average HbA1c (a three-month blood sugar measure) was 8.2% (The Lancet) [1].
What they took: Half were randomly assigned to the Foundayo pill once a day (up to the highest dose they could tolerate). The other half took insulin glargine, a long-acting insulin injection, once a day (The Lancet) [1].
How long: People were followed for a median of about two years (The Lancet) [1].
Main question: Was the pill "non-inferior" (not meaningfully worse) than insulin for major heart events, called MACE-4: heart-related death, non-fatal heart attack, non-fatal stroke, or hospital stay for unstable angina (The Lancet) [1]?
Open-label: Both patients and doctors knew which treatment each person received (The Lancet) [1].
What did the trial find about Foundayo heart safety?
The pill met its main goal. Major heart events occurred in 57 of 1,358 people on Foundayo (4.2%) and 67 of 1,343 people on insulin (5.0%). The hazard ratio was 0.84 (95% confidence interval 0.59 to 1.20) (The Lancet) [1].
In plain words: the pill was not worse than insulin for the heart. The numbers lean slightly in the pill's favour, but the range of uncertainty includes "no difference", so the trial does not prove the pill protects the heart better than insulin.
Outcome | Foundayo (pill) | Insulin glargine (injection) |
|---|---|---|
Major heart events (MACE-4) | 4.2% | 5.0% |
Deaths from any cause | 1.4% | 3.2% |
Stomach side effects | 62.1% | 14.2% |
Serious low blood sugar | 6.8% | 19.2% |
Body weight change at 1 year | about −8.8% | about +1.7% |
HbA1c change at 1 year | −1.6 points | −1.0 points |
Sources for table: The Lancet (heart events, deaths, side effects, low blood sugar); Eli Lilly (weight and HbA1c at 52 weeks).
Did Foundayo lower the risk of death?
Fewer people died in the pill group: 19 of 1,371 (1.4%) vs 43 of 1,355 (3.2%) on insulin (The Lancet) [1]. The company reported a hazard ratio of 0.43 for death from any cause and 0.47 for heart-related death (Eli Lilly) [2].
This sounds impressive, but it needs care:
Death was not the trial's main question. The company notes these analyses were "not controlled for family-wise type 1 error", meaning they were not protected against the extra chance of false findings that comes from testing many outcomes (Eli Lilly) [2].
The trial was open-label (not blinded), which can introduce bias (The Lancet) [1].
The company itself describes the result as "an association with a lower risk" of heart events and death, not proof of benefit (Eli Lilly) [2].
Another heart outcomes trial, ATTAIN-OUTCOMES, is under way in adults with obesity or overweight (with or without type 2 diabetes) and established heart or kidney disease (Eli Lilly) [2].
What about blood sugar, weight and other heart risk factors?
At 52 weeks, compared with insulin, people on the pill had a larger drop in HbA1c (−1.6 vs −1.0 points) and lost weight instead of gaining it. By two years, 35.9% on the pill had lost at least 10% of their body weight, compared with 3.4% on insulin (Eli Lilly) [2].
The company also reported changes at one year in the pill group, including a smaller waist (−7.0 cm), lower systolic blood pressure (−4.4 mmHg), lower triglycerides (−18.9%) and lower levels of an inflammation marker (hsCRP, −38.9%) (Eli Lilly) [2]. These are company-reported secondary results.
What are the side effects of Foundayo?
Stomach and gut side effects were the most common problem. They affected 62.1% of people on the pill vs 14.2% on insulin, and they were the most common reason people stopped the pill (The Lancet) [1]. The most frequent were nausea, vomiting, diarrhoea, reduced appetite and constipation. About 10.6% stopped the pill because of side effects in the first year (Eli Lilly) [2].
On the other hand, clinically significant or severe low blood sugar was much less common on the pill (6.8%) than on insulin (19.2%) (The Lancet) [1].
What are the limits of this study?
The ACHIEVE-4 trial has limits: it was open-label, compared Foundayo with insulin rather than placebo, was industry funded and studied only people with type 2 diabetes.
Open-label design: Knowing the treatment can affect how people and doctors behave and report problems.
Comparison with insulin, not placebo: The trial shows how the pill compares with insulin. It does not show how it compares with other GLP-1 medicines.
Industry funding: The trial was funded by Eli Lilly, the company that makes Foundayo (The Lancet) [1].
Specific group: Everyone had type 2 diabetes and existing heart or kidney disease. Results may not apply to people without diabetes who use Foundayo for weight loss.
Not yet approved for diabetes: In the US, Foundayo is approved for weight management only (Lilly Medical) [3].
What should you do with this news?
If you have type 2 diabetes and heart disease, the ACHIEVE-4 Foundayo trial is reassuring, but do not change any diabetes medicine without your doctor.
If you have type 2 diabetes and heart disease, this trial is reassuring: a GLP-1 pill did not raise heart risk compared with insulin.
Do not stop or switch insulin or any diabetes medicine on your own. Changes need a plan with your doctor, especially to avoid high or low blood sugar.
If you are curious about Foundayo, ask your doctor whether it fits your health, your other medicines and your goals.
Keep up the basics that protect your heart: blood pressure and cholesterol checks, not smoking, regular activity and a balanced diet (CDC) [4].
Frequently asked questions
Is Foundayo safe for the heart?
In the ACHIEVE-4 trial of people with type 2 diabetes and heart or kidney disease, Foundayo was not worse than insulin glargine for major heart events over about two years. That is the main finding on Foundayo heart safety so far (The Lancet).
Does Foundayo reduce the risk of heart attack or death?
Not proven. Heart events and deaths were lower with the pill, but the trial was designed to test safety, not benefit, and the death results were secondary analyses that need confirmation (Eli Lilly).
Is Foundayo approved for type 2 diabetes?
Not yet in the US. The FDA approved it on April 1, 2026, for weight management in adults with obesity, or overweight with a weight-related health condition (Lilly Medical).
What are the most common side effects of Foundayo?
Stomach problems such as nausea, vomiting, diarrhoea, reduced appetite and constipation. In this trial they affected 62.1% of people taking the pill (The Lancet; Eli Lilly).
Can I switch from insulin to Foundayo?
Only your doctor can decide that. This trial compared starting each treatment in a research setting; it does not tell individual patients to swap medicines.
Health information, not medical advice. This article explains new research for general education. It does not replace advice from your own doctor. Always talk to a qualified health professional before starting, stopping or changing any medicine.
Sources
Klein KR, Wysham C, Tuttle KR, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. The Lancet. 2026. Published online September 30, 2026. PMID 42815506. https://doi.org/10.1016/S0140-6736(26)01865-9
Eli Lilly and Company. Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study. Eli Lilly and Company. September 30, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-foundayo-orforglipron-demonstrated
Lilly Medical. Is Foundayo™ (orforglipron) approved, and is it available? Lilly Medical. Date of last review April 9, 2026. https://medical.lilly.com/us/products/answers/is-foundayo-orforglipron-approved-and-is-it-available-309937
Centers for Disease Control and Prevention. Diabetes and Your Heart. Centers for Disease Control and Prevention. May 15, 2024. https://www.cdc.gov/diabetes/diabetes-complications/diabetes-and-your-heart.html
Rosenstock J, Yabe D, Cox D, et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. The Lancet. 2026;407(10534):1147-1160. PMID 41765029. https://doi.org/10.1016/S0140-6736(26)00202-3
Giorgino F, D'Souza S, Ludwig L, et al. Orforglipron added to titrated insulin glargine in type 2 diabetes: the ACHIEVE-5 randomized clinical trial. JAMA. 2026;336(5):389-399. PMID 42251769. https://doi.org/10.1001/jama.2026.9512
Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine. 2026;32(7):2679-2687. PMID 42120723. https://doi.org/10.1038/s41591-026-04386-7
About the author: Dr. Baraa Alnahhal, MD, is a medical doctor and the founder of Rinnit. Dr. Baraa Alnahhal reviews new medical research and translates it into clear, evidence-based health information for everyday readers.




Comments